ECNP consensus meeting. Negative, depressive and cognitive symptoms of schizophrenia. Nice, March 2004

European Neuropsychopharmacology

Volumn 17, Issue 1, 2007, Pages 70-77

  Montgomery, S A ^a   van Zwieten Boot, B ^a  

^a NONE

Author keywords

Cognitive symptoms; Depressive symptoms; Negative symptoms; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; ZIPRASIDONE;

APATHY; ARTICLE; ATTENTION; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONSENSUS; DEPRESSION; DRUG EFFECT; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HAMILTON SCALE; HUMAN; MANIA; META ANALYSIS; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOTIVATION; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCHIZOPHRENIA; SUICIDE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WORKING MEMORY;

CLINICAL TRIALS; COGNITION DISORDERS; DEPRESSIVE DISORDER; GUIDELINES; HUMANS; MENTAL STATUS SCHEDULE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 33751343194     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2006.05.004     Document Type: Article

References (25)

1. A.P.A. Diagnostic and Statistical Manual of Mental Disorders DSM-IV (1994), American Psychiatric Association, Washington
2. A.P.A. Diagnostic Criteria from DSM-IV-TR (2000), American Psychiatric Association, Washington
3. Andreasen N.C. Positive vs. negative schizophrenia: a critical evaluation. Schizophr. Bull. 11 3 (1985) 380-389
4. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br. J. Psychiatry Suppl no. 7 (1989) 49-58
5. Donlon P.T., Rada R.T., and Arora K.K. Depression and the reintegration phase of acute schizophrenia. Am. J. Psychiatry 133 (1976) 1265-1268
6. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 153 3 (1996) 321-330
7. Hamilton M. Development of rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 6 (1967) 278-296
8. Harvey P.D., and Keefe R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry 158 2 (2001) 176-184
9. Hegarty J.D., Baldessarini R.J., Tohen M., Waternaux C., and Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am. J. Psychiatry 151 10 (1994) 1409-1416
10. Kay S.R., Opler L.A., and Lindenmayer J.P. The positive and negative syndrome scale (PANSS): rationale and standardization. Br. J. Psychiatry 155 Suppl. 7 (1989) 59-65
11. Knights A., and Hirsch S.R. Revealed depression and drug treatment for schizophrenic. Arch. Gen. Psychiatry 38 (1981) 800-811
12. Kraepelin E. Dementia praecox and paraphrenia (1999), Livingstone, Edinburgh
13. Leucht S., Pitschel-Walz G., Abraham D., and Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res. 35 1 (1999) 51-68
14. McGurk S.R., and Meltzer H.Y. The role of cognition in vocational functioning in schizophrenia. Schizophr. Res. 45 3 (2000) 175-184
15. Meltzer H.Y. Treatment-resistant schizophrenia - the role of clozapine. Curr. Med. Res. Opin. 14 1 (1997) 1-20
16. Meltzer H.Y., and McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25 2 (1999) 233-255
17. Moller H.J. Novel antipsychotics and negative symptoms. Int. Clin. Psychopharmacol. 13 Suppl 3 (1998) S43-S47
18. Montgomery S.A. Depressive symptoms in acute schizophrenia. Prog. Neuropsychopharmacol. 3 (1979) 429-433
19. Nemeroff C.B. Use of atypical antipsychotics in refractory depression and anxiety. J. Clin. Psychiatry 66 Suppl 8 (2005) 13-21
20. Roy A. Depression, attempted suicide, and suicide in patients with chronic schizophrenia. Psychiatr. Clin. North Am. 9 (1986) 193-206
21. Saykin A.J., Shtasel D.L., Gur R.E., Kester D.B., Mozley L.H., Stafiniak P., and Gur R.C. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch. Gen. Psychiatry 51 2 (1994) 124-131
22. Spohn H.E., and Strauss M.E. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J. Abnorm. Psychology 98 4 (1989) 367-380
23. Tohen M., Vieta E., Calabrese J., Ketter T.A., Sachs G., Bowden C., Mitchell P.B., Centorrino F., Risser R., Baker R.W., Evans A.R., Beymer K., Dube S., Tollefson G.D., and Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry 60 no. 11 (2003) 1079-1088
24. Tollefson G.D., and Sanger T.M. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am. J. Psychiatry 154 4 (1997) 466-474
25. Tsuang M.T., Woolson R.F., and Fleming J.A. Long-term outcome of major psychoses: I. Schizophrenia and affective disorders compared with psychiatrically symptom-free surgical conditions. Arch. Gen. Psychiatry 36 12 (1979) 1295-1301